A STUDY OF USE OF DMPA (INJECTABLE CONTRACEPTIVE) IN POSTPARTUM AND POSTABORTAL PATIENTS

Dr. Abhipsa Patel, Dr Jigar Thakkar, Dr Megha S Patel, Dr Saila Altaf khatri

Abstract


Background: Injectable depot-medroxyprogesterone acetate is a progestin-only, long acting contraceptive. It is proved safe, effective, reversible
and acceptable.
Aims and Objective: The objective of the study is to evaluate the safety and effectiveness of DMPA in postabortal and postpartum patients.
To study clinical presentation,outcome and side-effects of DMPA in postabortal and postpartum patients.
Materials and method: The type of study was prospective, interventional and a single centered study conducted in Department of Obstetrics and
Gynecology at L G Hospital, Maninagar, Ahmedabad. Study group received Inj. DMPA 150 mg intra muscularly immediately after abortion or
delivery before discharge from hospital (Day 2 to 7 of their delivery). They were given DMPA every 3 months.
Results: In present study, Out of 90 patients, 50 patients (55.55%) took injection post-delivery and 40 patients (44.44%) took it post abortion.
Irregular bleeding was major side effect seen in 55 patients (61.11%), amenorrhea seen in 26 (29%) patients, weight gain noted in 3 patients over 1
year. Other side effects were headache, backache, dyspareunia, erythema nodosum noted in 5 patients. In post-partum women, lactation remained
unaffected.
Conclusion: Patients prefer DMPA because it is non-coitus dependent, effective, long acting and other non-contraceptive benefits. No effect on
lactation. The return of fertility takes 7-10 months from date of last injection, but it is completely reversible.


Keywords


DMPA,Postabortal,Postpartum,Irregular bleeding

Full Text:

PDF

References


Kaunitz AM:Long acting injectable contraception with depot medroxyprogesterone acetate.Am J Obstet Gynecol;1997:170:1543

Cullins VE: Noncontraceptive benefits and therapeutic uses of depot medroxyprogesterone acetate. JReprod Med ;1996:41:S5:428

Reference manual for injectable contraceptive (DMPA) Family Planning Division Ministry of Health and Family Welfare Government of India available at : http://upnrhm.gov.in/site-files/family_planning/4.Manuals_of_FP-2015-16/Injectable_Manual

Kaunitz AM: Depot medroxyprogesterone acetate contraception and the risk of breast and gynecologic cancer. J Reprod Med ;1996:41:S5:419

Dadtey S, Gaur LN, Saxena BN. Vaginal bleeding patterns of women using different contraceptive methods (implants, injectables, IUDs, oral pills)--an Indian experience. An ICMR Task Force Study. Indian Council of Medical Research. Contraception. 1995 Mar;51(3):155-65.

Rai L, Prabakar P. Injectable depot medroxyprogesterone - a safe and an effective contraception for an Indian setting,” Health and Population Perspectives and Issues. 2007;30(1):12-

Michelle Fonseca*, Prasad Yashwant Deshmukh, Deepali Kharat

DMPA: acceptance and compliance in a tertiary care hospital in Mumbai, India Int J Reprod Contracept Obstet Gynecol. 2017 Sep;6(9):3879-3881

Ruchira Nautiyal1*, Rajeev Bijalwan2, B. Maithili2, Latika N. Sinha2Feasibility of injectable Depot medroxyprogesterone acetate in a semi urban camp setting Int J Reprod Contracept Obstet Gynecol. 2016 Apr;5(4):1056-1060

Singhal S, Sarda N, Gupta S. Impact of injectable Progestogen Contraception in early puerperium on Lactation and Infant health. J Clin Diagn Res. 2014;8(3):69-72.

Wu SC, Garceau RJ, Jiangs,Yang QZ, Wang WZ. Effect of pretreatment counseling on discontinuation rates in chinese women given Depot Medroxypregesterone acetate for contraception. Contraception. 1996;53(6):357-61.

Strategies to improve adherence and acceptability of hormonal methods of contraception .Cochrane database syst Rev. 2013;10:CD004317.

Hubacher D, Goco N, Gonzalez B, Taylor D. Factors effecting continuation rates of DMPA.Contraception. 1999;60;(6):345-51.

Karim M, Ammar R, El Mahgoub s et al: Injected togen and lactation.Br Med J 1971 1:200 ST.

Rodrigues MI, Kaunitz AM. An evidence of postpartum use of DMPA in breastfeeding women. Contraception. 2009;80(1):4-6.

Wu SC, Garceau RJ, Jiangs,Yang QZ, Wang WZ. Effect of pretreatment counseling on discontinuation rates in chinese women given Depot Medroxypregesterone acetate for contraception. Contraception. 1996;53(6):357-61.

Strategies to improve adherence and acceptability of hormonal methods of contraception .Cochrane database syst Rev. 2013;10:CD00431.

Speroff L, Darney PD (2005). "Injectable Contraception". A Clinical Guide for Contraception (4th ed.).

Faculty of Sexual & Reproductive Healthcare. Progestogen-only injectable contraception: FSRH. 2015. Available from: http://www.fsrh.org/pdfs/CEUGuidanceProgestogenOnlyInjectables.pd

Pardthaisong T. Return of fertility after use of the injectable contraceptive Depo Provera: up-dated data analysis.

J Biosoc Sci. 1984 Jan;16(1):23-34.

Hubacher D, Goco N, Gonzalez B, Taylor D. Factors effecting continuation rates of DMPA.Contraception. 1999;60;(6):345-51.


Refbacks

  • There are currently no refbacks.